HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Ishita Drugs & Industries Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 27 filings·Updated 8 Aug 2026
Showing 10 of 27 filings.
8 Aug 20261 filing
Board MeetingOutcome of Board Meeting

Ishita Drugs approves Q1 2026 unaudited results; CFO remuneration; AGM notice amendment; director reappointment; upgradation progress

Financial results

  • Unaudited quarterly results for quarter ended 30 June 2026 approved; Limited Review Report attached.

AGM amendments

  • Notice for the 33rd AGM amended and approved.

Remuneration

  • Revised remuneration approved for CFO Sumit Agrawal.

Director reappointment

  • Re-appoint Abha Agrawal as Non-Executive Non-Independent Director beyond age 75; subject to shareholder approval; not debarred.

Governance/compliance

  • Board composition compliant with Companies Act 2013 and SEBI Listing Regulations.

Upgradation project

  • Manufacturing facility upgrade for Schedule M; new warehouse block completed; 435 lakh spent; 565 lakh contracts issued.

Regulatory disclosures

  • Annexure I with disclosures attached; no material regulatory issues noted.
Filed 15:35View Source
31 Jul 20261 filing
Board Meeting

Board Meeting filing for Ishita Drugs & Industries Ltd identified; no date/time or agenda details present

Meeting context

  • Board meeting filing for Ishita Drugs & Industries Ltd (scrip 524400) identified.
Filed 13:56View Source
9 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5) certificate: dematerialisation processed, listings confirmed, certificates mutilated, ownership updated

Dematerialisation processing and listing status

  • Dematerialisation requests processed and confirmed to the depositories.
  • Securities dematerialised listed on the stock exchange where previously listed.
  • Physical certificates received for dematerialisation mutilated and cancelled after verification; depository name updated as registered owner.
Filed 14:08View Source
13 Apr 20261 filing
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation

Non - applicability of Regulation 32(1) of SEBI(LODR) Regulations, 2015 for the year ended 31st March, 2026.

Filed 15:23View Source
26 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday, 01st April, 2026 till 48 hours after the declaration of the Audited Financial ....

Filed 14:11View Source
27 Feb 20261 filing
Company UpdateGeneral

Disclosure under regulation 29(2) of SEBI(SAST) Regulations, 2011 received from Ishita Pharmaceuticals, related party of Ishita Drgs and Industrie Limited.

Filed 17:27View Source
7 Feb 20262 filings
ResultFinancial Results

Ishita Drugs & Industries Ltd - 524400 - Outcome Of Board Meeting Held On 07Th February, 2026

Financial Performance 📊

  • Board approved unaudited financial results for Q3 and nine months ended Dec 31, 2025.
  • Limited Review Report issued with no material misstatement or qualification by auditors.

Capex & Operations 🧱

  • Rs 100 lakh capital expenditure incurred till Dec 31, 2025.
  • Rs 65 lakh spent on civil works till Dec 31, 2025.
  • Manufacturing facility upgrade for Revised Schedule M compliance significantly progressed.
  • New warehouse block construction nearly completed; repairs and renovations ongoing.
  • Orders placed for utilities and equipment for Revised Schedule M compliance.
Filed 15:54View Source
Board MeetingOutcome of Board Meeting

Ishita Drugs & Industries Ltd - 524400 - Board Meeting Outcome for Outcome Of Board Meeting Held On 07Th February, 2026

Financial Performance 📊

  • Approved unaudited standalone financial results for quarter and nine months ended 31 Dec 2025.
  • Statutory auditors issued limited review report with no material misstatements or qualifications.

Capital Expenditure and Facility Upgrades 📍

  • Incurred Rs. 65 lakhs on civil works and Rs. 100 lakhs on capital expenditure for facility upgrades as of 31 Dec 2025.
  • New warehouse block construction nearly completed.
  • Placed orders for utilities and equipment for Revised Schedule M compliance.
Filed 15:41View Source
30 Jan 20261 filing
Board Meeting

Ishita Drugs & Industries Ltd - 524400 - Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended 31St December, 2025

🗓️ Meeting Details

  • Board meeting scheduled for Saturday, 7 February 2026.

📊 Key Agenda Items

  • Approval and recording of unaudited financial results for Q3 ended 31 December 2025.
Filed 15:20View Source
2 Jan 20261 filing
Company UpdateGeneral

Change in Address of our RTA i.e. Bigshare Services Private Limited (Ahmedabad Branch)

Filed 14:19View Source
Showing 10 of 27 filings